Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

Last week’s earnings call didn’t deliver what Merck & Co. ($MRK) investors were hoping for. While the company posted what ...

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

Merck & Co. is taking full control of MK-8690, an investigational drug targeting inflammatory bowel diseases that was part of the drugmaker's $10.8 billion acquisition of Prometheus Biosciences in ...

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

Five top-selling drugs, in some cases, are costing Americans thousands in out of pocket expenses weekly and monthly. Here's ...

Wondering if Merck stock is truly a bargain or just priced for perfection? You are not alone. Let's dig into what the numbers ...

Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Merck also lowered revenue guidance for 2025. 10 stocks we like better than Merck › The stock for pharmaceutical giant Merck ...